CAR T and CAR NK cells in multiple myeloma: Expanding the targets-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

CAR T and CAR NK cells in multiple myeloma: Expanding the targets

Published:2020-03 Issue:1 Volume:33 Page:101141
ISSN:1521-6926
Container-title:Best Practice & Research Clinical Haematology
language:en
Short-container-title:Best Practice & Research Clinical Haematology

Author:

Shah Urvi A.,Mailankody Sham

Funder

Celgene

National Cancer Institute

Takeda Oncology

Juno/Celgene

Janssen and Allogene Therapeutics

Publisher

Elsevier BV

Subject

Clinical Biochemistry,Oncology

Reference88 articles.

1. Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients;Kumar;Leukemia,2014

2. Trends in overall survival and costs of multiple myeloma;Fonseca;Leukemia,2017

3. Immune therapies in multiple myeloma;Kumar;Clin Cancer Res,2016

4. Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial;Lonial;Lancet,2016

5. Clinical efficacy of daratumumab monotherapy in patients with heavily pretreated relapsed or refractory multiple myeloma;Usmani;Blood,2016

Cited by 40 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Antibody-drug conjugates, bispecific antibodies and CAR-T cells therapy in multiple myeloma;Expert Review of Anticancer Therapy;2024-05-26

2. Acute myeloid leukemia relapse after allogeneic hematopoietic stem cell transplantation presenting as pericardial effusion;Blood Science;2023-10

3. CAR T cell therapy in multiple myeloma, where are we now and where are we heading for?;European Journal of Haematology;2023-08-07

4. Breaking down barriers: The potential of smarter CAR‐engineered NK cells against solid tumors;Journal of Cellular Biochemistry;2023-08

5. Real-life experiences with CAR T-cell therapy with idecabtagene vicleucel (ide-cel) for triple-class exposed relapsed/refractory multiple myeloma patients;BMC Cancer;2023-04-15

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3